Skip to main
SLDB
SLDB logo

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences Inc is making significant strides in addressing Duchenne muscular dystrophy (DMD) through its innovative pipeline, with projections indicating that SGT-003 could generate risk-adjusted revenues of $1 billion by 2033, up from $90 million in 2028. Promising early clinical data demonstrates improvements in cardiac function and key biomarkers indicative of enhanced muscle integrity, suggesting strong underlying efficacy for the company's gene therapy approach. Additionally, the company is adapting its evaluation metrics to better capture functional benefits over more extended analysis periods, reinforcing the potential for expanded market reach and validation of its therapeutic technologies.

Bears say

Solid Biosciences Inc faces significant risks that contribute to a negative outlook for its stock. The primary concern stems from the uncertainty surrounding regulatory approval for its lead gene therapy candidate, SGT-003, with potential failure to secure approval or delays leading to downward revisions in risk-adjusted projections and price targets. Additionally, the company may struggle with manufacturing capacity limitations, which could materially constrain sales of SGT-003, exacerbating financial instability amid broader industry challenges in gene therapy development.

Solid Biosciences (SLDB) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 21 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.